Scientists guilty of 'hyping' benefits of gene research
By The Independent,
The Independent (UK)
| 09. 05. 2005
The leading fertility scientist Lord Winston has hit out at senior scientists, including two Nobel laureates, for making exaggerated claims about the supposed benefits of scientific research, warning they could trigger a public backlash.
Speaking on the eve of his presidential address to the annual meeting of the British Association for the Advancement of Science at Trinity College, Dublin, the former head of fertility medicine at the Hammersmith Hospital in London also criticised the "hype" over stem cells. He said stem cells are unlikely to be of much use for many years.
Lord Winston called on his colleagues to use more moderate language when describing scientific breakthroughs, singling out in his speech senior scientists and naming two Nobel laureates for making dangerously arrogant remarks.
"James Watson's assertion about the value of tampering with the human germ-line are a pretty good example," he said. Professor Watson, who won a Nobel prize for discovering the DNA double helix with Francis Crick, has extolled the possibility of altering the genes of germ-line sperm or egg cells to eradicate inherited diseases.
Lord Winston also...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...